EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member
10 Mayo 2024 - 10:45AM
Business Wire
EGLE Therapeutics, a clinical-stage biotechnology company
uniquely positioned to advance the next generation of regulatory T
cell-focused therapies for oncology and auto-immunity, announced
today the appointment of Pejvack Motlagh MD, MSc, as Chief Medical
Officer and John Celebi, as Independent Board Member.
“We are excited to welcome Pejvack and John at Egle and to
benefit from their strong experience.
The appointment of Dr Motlagh is critical for Egle, as the
company is moving to clinical development of assets in oncology and
auto-immunity. Pejvack will impact the future development of the
rich pipeline at Egle, based on the modulation of regulatory T
cells.
As we advance toward the clinical development of EGL-001, John’s
expertise in business development in the field of oncology is
instrumental for us to successfully execute on our strategic
priorities.” said Vincent Brichard, M.D., EGLE’s Interim CEO and
Board member.
“I am excited to join Egle Therapeutics to translate into the
clinic the company's groundbreaking and unique science, whose
innovative and versatile regulatory T-cell focused platform, a key
component of the immune system, has a tremendous potential to
change the treatment paradigm for the many patients with high unmet
medical needs in oncology and auto-immunity” said Pejvack Motlagh,
MD, MSc, CMO at Egle Therapeutics. As CMO, Pejvack will drive the
clinical and medical strategy and development of our Company in the
years to come.
“This is a transformational period for Egle Therapeutics as the
company further strengthens its team and advances toward the clinic
a series of highly novel candidates aimed at arming or disarming
Treg function to achieve the desired therapeutic outcome. I look
forward to collaborating with this talented Board and management
team as we advance Egle’s compelling pipeline for patients with
unmet need,” said John Celebi, Independent Board Member at Egle
Therapeutics.
Pejvack Motlagh, MD, MSc, a seasoned clinical development
executive who has previously held overall responsibility for
candidate development from first in human through registrational
studies, brings to Egle Therapeutics the appropriate expertise and
successful drug development experience. As Chief Medical Officer,
he will be responsible for advancing Egle’s pipeline towards the
clinic and notably EGL-001 (a Treg-selective anti-CTLA4-IL-2m) in
oncology and EGL-003 (a non-targeted IL-2 Treg engager) in
auto-immune diseases. Prior to Egle Therapeutics, Dr. Motlagh was
Chief Medical Officer at Mablink, an ADC biotech company, where
through the establishment of a differentiating clinical development
plan he contributed to the value creation leading to an acquisition
by Eli Lilly. Previously, he held global positions at leading
oncology companies such as GSK, Bristol-Myers Squibb and
AstraZeneca, where he was instrumental in the transition of several
compounds towards the late clinical development phases of now
approved drugs. At Boehringer Ingelheim, he oversaw, managed and
prioritized their whole IO portfolio.
John Celebi, MBA, brings over 25 years of experience
building innovative entrepreneurial biotechnology companies. He
currently serves as President and CEO of Sensei Biotherapeutics
(NASDAQ: SNSE), a biotechnology company focused on the discovery
and development of novel immunotherapies for cancer patients with
unmet needs. Previously, Mr. Celebi served as the Chief Operating
Officer of X4 Pharmaceuticals where he established and oversaw the
company’s oncology business strategy. He also served as Chief
Business Officer of Igenica Biotherapeutics, Inc., an immunotherapy
company formed by The Column Group, 5AM Ventures, Orbimed, and
Third Rock Ventures, where he established key academic and industry
relationships, including with MedImmune. Mr. Celebi has extensive
transactional and alliance management experience, having served as
Vice President of Business Development, New Product Planning and
Alliance Management at ArQule, Inc., where he played a central role
in the formation of alliances with Roche, Daiichi-Sankyo, and Kyowa
Hakko Kirin. Mr. Celebi was an early employee at Tularik, Inc.,
where he conducted drug discovery and basic research. Mr. Celebi
received an MBA from Carnegie Mellon University and a B.S. in
biophysics from the University of California, San Diego.
About Egle Therapeutics SAS (Egle)
Egle Therapeutics is a biotechnology company focused on
developing immunotherapies targeting suppressive regulatory T
cells. Egle is leveraging a proprietary discovery platform to
unveil novel Treg specific targets and to develop innovative
Treg-focused drug candidates for oncology and autoimmune diseases.
Egle aspires to advance toward the clinic its most advanced drug
candidates, EGL-001 (a Treg-selective anti-CTLA4-IL-2m) and EGL-003
(non-targeted IL-2 Treg engager), which are currently developed in
IND-enabling studies.
Find out more at www.egle-tx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240510313711/en/
contact@egle-tx.com / 0033 (0)1 86 64 08 57
investor.relations@egle-tx.com / 0033 (0)1 86 64 08 57